HD-OPM Archive
Topics › LDL, ApoB & lipid panel

NLA consensus: apoB testing helps when LDL-C and risk are discordant

Gokhan Can · Oct 15, 2024 · ♥ 13 reactions · 6 comments · original Facebook post
LDL, ApoB & lipid panelRisk assessment & lab testsGuidelines, policy & public health
AI summary & key facts

Summary of a National Lipid Association expert consensus on apoB testing. ApoB counts all atherogenic particles and may predict risk better than LDL-C, especially after statin treatment when the two diverge, and testing is suggested for borderline-risk patients deciding on a statin and in other discordant cases.

ApoB Testing in Lipid Management: New Guidelines Clarify Role and Importance

The article discusses new guidelines for apolipoprotein B (apoB) testing in lipid management, as outlined by the National Lipid Association's Expert Clinical Consensus. ApoB is a protein found on all atherogenic lipoproteins and is considered a more accurate predictor of cardiovascular risk than LDL cholesterol (LDL-C) alone. While apoB and LDL-C levels often correlate, they can diverge in some individuals, particularly after statin treatment. In such cases, apoB remains a better indicator of cardiovascular outcomes, potentially leading to more accurate risk assessment and treatment decisions.

The consensus statement suggests that apoB testing may be particularly useful in two scenarios: for patients with borderline cardiovascular disease risk who are deciding whether to start statin therapy, and for those already on statins who are considering treatment intensification. The guidelines provide specific apoB treatment thresholds that correspond to established LDL-C goals. However, the statement emphasizes that routine apoB measurement is not necessary for all patients and remains a matter of clinical judgment. It may be most beneficial for individuals with conditions such as hypertriglyceridemia, diabetes, visceral adiposity, insulin resistance, metabolic syndrome, low HDL-C, or very low LDL-C levels.

MedscapeHeard of ApoB Testing? New GuidelinesDr Neil Skolnik highlights the key points for primary care clinicians from a new consensus statement on apolipoprotein B testing.medscape.com

Research cited

#apob#guidelines#cardiovascular#statins#cardiovasculardisease#insulinresistance#metabolicsyndrome#lowldl
← newer: Bempedoic acid cut CV events 30% and all-cause death 27% in older: Bisphosphonates for bone loss: fracture reductions summarize →